ProKidney (PROK)
Develops rilparencel for advanced chronic kidney disease and type 2 diabetes.
$1.76
vs last close−0.07 (−4.06%)
Something off on this page? Send us feedback.
Next report
Nov 9, 26
in 47 days
EPS estimate
−$0.12
Revenue estimate
$124.6K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.17−$0.13−$0.13−$0.12−$0.14−$0.14−$0.15Pending
Estimate−$0.14−$0.16−$0.14−$0.12−$0.16−$0.13−$0.14−$0.12
Surprise−21.4%+18.8%+7.1%0.0%+12.5%−7.7%−7.1%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$76.0K$230.0K$221.0K$217.0K$223.0K$226.0K$150.0KPending
Estimate——$44.3K—$600$100.3K$186.3K$124.6K
Surprise——+399.4%—+37,066.7%+125.4%−19.5%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.12 | — | — |
| Sep 2027 | −$0.10 | — | — |
| Jun 2027 | −$0.11 | — | — |
| Mar 2027 | −$0.16 | — | — |
| Dec 2026 | −$0.33 | — | — |
| Nov 2026 | −$0.12 | — | — |
| Aug 2026 | −$0.14 | −$0.15 | −7.1% |
| May 2026 | −$0.13 | −$0.14 | −7.7% |
| Mar 2026 | −$0.16 | −$0.14 | +12.5% |
| Nov 2025 | −$0.12 | −$0.12 | 0.0% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| Mar 2021 | |||
| Dec 2020 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.12 | — | — | $200.0K | — | — | — |
| Sep 2027 | −$0.10 | — | — | $200.0K | — | — | — |
| Jun 2027 | −$0.11 | — | — | $200.0K | — | — | — |
| Mar 2027 | −$0.16 | — | — | $200.0K | — | — | — |
| Dec 2026 | −$0.33 | — | — | $453.4K | — | — | — |
| Nov 9, 2026 | −$0.12 | — | — | $124.6K | — | — | — |
| Aug 10, 2026 | −$0.14 | −$0.15 | −7.1% | $186.3K | $150.0K | −19.5% | −4.7% |
| May 15, 2026 | −$0.13 | −$0.14 | −7.7% | $100.3K | $226.0K | +125.4% | −2.9% |
| Mar 18, 2026 | −$0.16 | −$0.14 | +12.5% | $600 | $223.0K | +37,066.7% | −2.4% |
| Nov 10, 2025 | −$0.12 | −$0.12 | 0.0% | — | $217.0K | — | −6.6% |
| Aug 12, 2025 | |||||||
| May 12, 2025 | |||||||
| Mar 17, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 9, 2024 | |||||||
| May 10, 2024 | |||||||
| Mar 21, 2024 | |||||||
| Nov 14, 2023 | |||||||
| Aug 10, 2023 | |||||||
| May 11, 2023 | |||||||
| Mar 28, 2023 | |||||||
| Nov 14, 2022 | |||||||
| Aug 12, 2022 | |||||||
| May 16, 2022 | |||||||
| Mar 24, 2022 | |||||||
| Nov 15, 2021 | |||||||
| Aug 16, 2021 | |||||||
| Mar 31, 2021 | |||||||
| Dec 31, 2020 |